BioNTech CEO Ugur Sahin sells 64K shares

BioNTech’s CEO Ugur Sahin executed pre-arranged Rule 10b5-1 sales totaling 64,000 shares while maintaining over 39 million shares indirectly via Medine GmbH.

Rhea-AI Filing Summary

BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 64,000 Ordinary Shares in open-market or private transactions on September 17–18, 2026, at weighted-average prices of $98.5983 and $96.2243 per share, respectively, under a Rule 10b5-1 trading plan established on June 3, 2026.

Following these transactions, an entity associated with Sahin, Medine GmbH, holds 39,218,111 Ordinary Shares indirectly attributed to him, including 106,721 Ordinary Shares held in trust where Medine GmbH exercises voting power but not dispositive power, and Sahin may be deemed to beneficially own these shares.

Insider Trade Summary 10b5-1

Net Seller: 64,000 shares

Net Sell 3 txns

Insider Sahin Ugur

Role Chief Executive Officer

Sold 64,000 shs ($6.24M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	30,000	$96.2243	$2.89M
Sale	Ordinary Shares	34,000	$98.5983	$3.35M
holding	Ordinary Shares F1	--	--	--

Holdings After Transaction: Ordinary Shares — 489,209 shares (Direct); Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)

Footnotes (1)

1. F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Key Figures

Shares sold September 18, 2026: 30,000 Ordinary Shares Sale price September 18, 2026: $96.2243 per share Shares sold September 17, 2026: 34,000 Ordinary Shares +5 more

8 metrics

Shares sold September 18, 2026 30,000 Ordinary Shares Open-market or private sale reported for September 18, 2026

Sale price September 18, 2026 $96.2243 per share Weighted-average price for 30,000-share sale on September 18, 2026

Shares sold September 17, 2026 34,000 Ordinary Shares Open-market or private sale reported for September 17, 2026

Sale price September 17, 2026 $98.5983 per share Weighted-average price for 34,000-share sale on September 17, 2026

Total shares sold 64,000 Ordinary Shares Combined sales on September 17–18, 2026

Indirectly held shares via Medine GmbH 39,218,111 Ordinary Shares Indirect ownership position attributed to Sahin through Medine GmbH

Trust-held shares with only voting power 106,721 Ordinary Shares Held in trust where Medine GmbH has voting but not dispositive power

Rule 10b5-1 plan adoption date June 3, 2026 Date Sahin established the trading plan governing the reported sales

Key Terms

Rule 10b5-1 trading plan, beneficially own, dispositive power, voting power, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"sales were effected pursuant to a Rule 10b5-1 trading plan established"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

beneficially own regulatory

"The reporting person may be deemed to beneficially own the ordinary"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

dispositive power regulatory

"exercises voting power, but not dispositive power, over such ordinary"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

voting power regulatory

"Medine GmbH exercises voting power, but not dispositive power, over"

Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.

Indirect ownership financial

"The ordinary shares are held by Medine GmbH. The reporting person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BioNTech (BNTX) CEO Ugur Sahin report on this Form 4?

He reported two sales totaling 64,000 Ordinary Shares: 34,000 shares on September 17, 2026 at $98.5983 per share and 30,000 shares on September 18, 2026 at $96.2243 per share, described as open-market or private transactions.

Were the recent BNTX share sales by Ugur Sahin made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan that Sahin established on June 3, 2026, indicating they followed a pre-arranged trading schedule.

How many BioNTech (BNTX) shares are indirectly attributed to Ugur Sahin after these trades?

An entity associated with him, Medine GmbH, holds 39,218,111 Ordinary Shares. Sahin is the sole shareholder of Medine GmbH and may be deemed to beneficially own these shares according to the filing.

What is the nature of BioNTech (BNTX) shares held in trust mentioned in the Form 4?

Of the shares held by Medine GmbH, 106,721 Ordinary Shares are held for the benefit of an individual under a trust. Medine GmbH has voting power but not dispositive power over these trust shares for so long as they remain in trust.

Does Ugur Sahin have direct or indirect ownership of the reported BNTX shares?

The 64,000 shares sold were held directly by Sahin. The 39,218,111 Ordinary Shares reported as a holding entry are held indirectly through Medine GmbH, for which he is the sole shareholder and may be deemed a beneficial owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:42 PM Accepted by SEC EDGAR 09/18/2026 - 04:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sahin Ugur

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/17/2026		S		34,000	D	$98.5983	519,209	D
Ordinary Shares	09/18/2026		S		30,000	D	$96.2243	489,209	D
Ordinary Shares								39,218,111	I	See Footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Remarks:

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.

	/s/ Humza Bokhari, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)